NON-MUSCLE-INVASIVE BLADDER CANCER
Clinical trials for NON-MUSCLE-INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE-INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for NON-MUSCLE-INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot for bladder tumors shows promise in early trial
Disease control Recruiting nowThis early-stage study is testing a new drug, belzupacap sarotalocan, injected directly into bladder tumors to see if it's safe and doable for people with non-muscle-invasive bladder cancer. About 55 participants will receive the injection, sometimes with a laser, and be monitore…
Matched conditions: NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated May 17, 2026 04:11 UTC
-
New hope for bladder cancer: Catheter-Delivered drug tested
Disease control Recruiting nowThis study tests a new drug called 2141-V11 for safety in people with a type of bladder cancer that didn't get better with standard treatment. The drug is given directly into the bladder through a tube (catheter). About 55 people will take part to find the safest dose and see how…
Matched conditions: NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New bladder rinse aims to calm cancer Treatment's harsh side effects
Symptom relief Recruiting nowThis study is for 200 adults with non-muscle invasive bladder cancer who are getting standard chemotherapy (MMC) or immunotherapy (BCG) directly into the bladder. Half will also receive a special bladder rinse called Hydeal Cyst® after each treatment. The goal is to see if this r…
Matched conditions: NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated May 06, 2026 16:02 UTC